THE RISE OF HUMIRA BIOSIMILARS
For over two decades, Humira (adalimumab) has transformed the treatment of autoimmune diseases. Since its debut in 2002, this groundbreaking biologic has become a trusted cornerstone in managing conditions like rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. Members who once had limited treatment options found new hope with Humira, thanks to its ability to reduce inflammation and improve quality of life.
But there’s one major challenge: cost. Humira has long been one of the most expensive drugs on the market, placing a heavy financial burden on members and healthcare systems. The good news? Biosimilars have arrived – offering similar efficacy at a lower price.
What Are Biosimilars?
Think of biosimilars as highly similar, more affordable versions of a biologic drug. The FDA requires that biosimilars demonstrate no clinically meaningful differences from the original drug in terms of safety, effectiveness, and quality. While not exact copies (like generics for traditional drugs), biosimilars undergo rigorous testing to confirm that they offer comparable clinical performance to the reference product.
The Humira Biosimilar Revolution
Since Amjevita became the first Humira biosimilar to receive FDA approval in 2016, a wave of new options has entered the market. As of 2024, the U.S. has 10 FDA-approved Humira biosimilars, all competing to offer effective treatment at lower costs.
Biosimilar Product |
FDA Approval Date |
Notable Feature |
| Amjevita (adalimumab-atto) | Sept 2016 | First Humira biosimilar approved |
| Abrilada (adalimumab-afzb) | Nov 2019 | – |
| Cyltezo (adalimumab-adbm) | Aug 2017 | First interchangeable biosimilar |
| Hadlima (adalimumab-bwwd) | July 2023 | – |
| Hulio (adalimumab-fkjp) | July 2020 | – |
| Hyrimoz (adalimumab-adaz) | July 2023 | – |
| Idacio (adalimumab-aacf) | Dec 2022 | – |
| Simlandi | Feb 2024 | First high-concentration and citrate-free interchangeable biosimilar |
| Yusimry (adalimumab-aqvh) | Dec 2021 | – |
| Yuflyma (adalimumab-aaty) | May 2023 | – |
What This Means for Members
More biosimilars mean more competition, which drives down costs. With biosimilars priced lower than Humira, members have greater access to life-changing treatments without the financial strain. Lower drug costs also reduce spending for employers, health plans, and the overall healthcare system – a win for everyone.
CerpassRx’s Approach: Making Biosimilars a Priority
At CerpassRx, we are committed to transitioning from Humira to preferred biosimilars – delivering 80-90% savings across our book of business while maintaining the same clinical safety and effectiveness.
Our Preferred Humira Biosimilars:
Biosimilar |
Brand Name |
Interchangeable with Humira? |
Formulation | FDA-Approved Indications |
| Simlandi | adalimumab-ryvk | Yes | Standard | RA, CD, UC, AS, PsA, PsO, HS, JIA, Uveitis |
| Cyltezo | adalimumab-adbm | Yes | Citrate-free | RA, CD, UC, AS, PsA, PsO, HS, JIA, Uveitis |
| Unbranded adalimumab-adbm | Cyltezo | Yes | Citrate-free | RA, CD, UC, AS, PsA, PsO, HS, JIA, Uveitis |
| Unbranded adalimumab-adaz | Hyrimoz | Yes | Standard | RA, CD, UC, AS, PsA, PsO, HS, JIA, Uveitis |
Considerations for Members & Healthcare Providers
While biosimilars promise affordability and accessibility, there are key factors to consider:
- Interchangeability: Some biosimilars can be substituted without a prescriber’s intervention, while others require a new prescription.
- Member Confidence: Some members may be hesitant to switch due to concerns about effectiveness.
- Insurance Coverage: Formularies vary, so checking with a PBM like CerpassRx is essential to understanding which biosimilars are covered.
A New Era of Cost-Effective Treatment
The rise of Humira biosimilars marks a major step forward in making advanced autoimmune treatments more affordable. By adopting biosimilars, healthcare systems may realize significant cost savings while continuing to provide access to high-quality care options.
The biosimilar revolution is here – and we’re just getting started! Stay tuned as more innovations continue to reshape the future of pharmacy benefits.
References:
- S. Food & Drug Administration. Biosimilars Basics for Members. FDA.gov. August 1, 2024. Accessed March 7, 2025. https://www.fda.gov/drugs/biosimilars/biosimilars-basics-members
- The American Journal of Managed Care. The Center For Biosimilars. March 7, 2025. https://www.centerforbiosimilars.com/biosimilar-approvals
- Cross R.K., Stewart A.L., Edgerton C.C. et al. Implementation Strategies of Biosimilars in Healthcare Systems: The Path Forward. Am Health Drug Benefits. 2022;15(2):45-53.
- com. What biosimilars have been approved in the United States? February 18, 2025. Accessed March 7, 2025. https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/
ABOUT CERPASSRX
CerpassRx, a leading full-service PBM, is renowned for its tailored solutions addressing diverse client needs. Its distinctive approach encompasses prescription optimization programs, flexible formulary designs, personalized member services, and efficient mail delivery and specialty pharmacy programs. Integrating top-tier pharmacy tools and expertise with premier PBM services, CerpassRx exemplifies excellence. Central to its core values are collaboration, accountability, passion, and empowerment. By prioritizing these principles, CerpassRx empowers clients, fostering an alliance built on trust and mutual success. The company’s mission is clear: to redefine standards and push boundaries, ultimately driving positive change and heightened efficiency in pharmacy benefit management.